RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kangmei Pharmaceutical Co Stock

Kangmei Pharmaceutical Co ROA 2024

Kangmei Pharmaceutical Co ROA

0.01

Ticker

600518.SS

ISIN

CNE0000017M1

In 2024, Kangmei Pharmaceutical Co's return on assets (ROA) was 0.01, a -104.05% increase from the -0.18 ROA in the previous year.

Kangmei Pharmaceutical Co Aktienanalyse

What does Kangmei Pharmaceutical Co do?

Kangmei Pharmaceutical Co. Ltd is a Chinese company that was founded in 1997. It is headquartered in the city of Lianyungang in the Jiangsu province and has been listed on the Shanghai Stock Exchange since 2001. With a market capitalization of over 15 billion US dollars, it is one of the leading pharmaceutical companies in the country. The company's business model is based on the development, production, and distribution of pharmaceutical products and medical devices. It is divided into several divisions, including drugs for colds, diabetes, cancer, and other diseases, dietary supplements, contrast agents for X-rays, as well as medical devices such as infusion pumps, blood pressure monitors, and ultrasound machines. Kangmei has focused heavily on the domestic market in recent years and is present in all provinces of China. It operates over 30 subsidiaries throughout the country and has more than 10,000 employees. The company is committed to improving healthcare in China and developing innovative products for the domestic market. One of Kangmei's most well-known drugs is "Ganmaoling Granule," a traditional Chinese medicine for treating colds and flu. It has been in production for over 30 years and is very popular in China. Kangmei also produces various drugs for the treatment of diabetes, including insulin preparations and oral medications. Another important area for Kangmei is the development of cancer drugs. The company specializes in researching and developing innovative therapies for various types of cancer. It has introduced several products to the market that can be used in the treatment of lung cancer, breast cancer, and other tumors. In addition to its pharmaceutical products, Kangmei has also developed a range of dietary supplements, such as "Qingkailing Capsules," which are made from natural ingredients and are intended to strengthen the immune system. These products are very popular in China and also contribute to Kangmei's diversification of its business operations. Kangmei has also specialized in the production of medical devices. It has developed a wide range of products such as infusion pumps, dialysis machines, and ultrasound devices. These devices are in high demand in China and other countries around the world, such as Africa and Latin America. Overall, Kangmei has established a strong presence in the Chinese pharmaceutical and medical market and is well-positioned to benefit from the strong growth of the healthcare sector in China. The company focuses on innovation and invests heavily in research and development of new products. It aims to play a leading role in the Chinese healthcare industry while contributing to the improvement of healthcare services. Kangmei Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Kangmei Pharmaceutical Co's Return on Assets (ROA)

Kangmei Pharmaceutical Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Kangmei Pharmaceutical Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Kangmei Pharmaceutical Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Kangmei Pharmaceutical Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Kangmei Pharmaceutical Co stock

What is the Return on Assets (ROA) of Kangmei Pharmaceutical Co this year?

The Return on Assets (ROA) of Kangmei Pharmaceutical Co is 0.01 undefined this year.

What was the ROA of Kangmei Pharmaceutical Co compared to the previous year?

The ROA of Kangmei Pharmaceutical Co has increased by -104.05% compared to the previous year.

What consequences do high ROA have for investors of Kangmei Pharmaceutical Co?

A high ROA is advantageous for investors of Kangmei Pharmaceutical Co, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Kangmei Pharmaceutical Co?

A low ROA can be unfavorable for investors of Kangmei Pharmaceutical Co as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Kangmei Pharmaceutical Co affect the company?

An increase in ROA of Kangmei Pharmaceutical Co can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Kangmei Pharmaceutical Co impact the company?

A reduction in the ROA of Kangmei Pharmaceutical Co can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Kangmei Pharmaceutical Co?

Some factors that can influence the ROA of Kangmei Pharmaceutical Co include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Kangmei Pharmaceutical Co important for investors?

The ROA of Kangmei Pharmaceutical Co is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Kangmei Pharmaceutical Co take to improve ROA?

To improve ROA, Kangmei Pharmaceutical Co can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Kangmei Pharmaceutical Co pay?

Over the past 12 months, Kangmei Pharmaceutical Co paid a dividend of 0.02 CNY . This corresponds to a dividend yield of about 1.31 %. For the coming 12 months, Kangmei Pharmaceutical Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Kangmei Pharmaceutical Co?

The current dividend yield of Kangmei Pharmaceutical Co is 1.31 %.

When does Kangmei Pharmaceutical Co pay dividends?

Kangmei Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of June, July, August, September.

How secure is the dividend of Kangmei Pharmaceutical Co?

Kangmei Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Kangmei Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kangmei Pharmaceutical Co located?

Kangmei Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kangmei Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kangmei Pharmaceutical Co from 8/28/2019 amounting to 0.024 CNY, you needed to have the stock in your portfolio before the ex-date on 8/28/2019.

When did Kangmei Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 8/28/2019.

What was the dividend of Kangmei Pharmaceutical Co in the year 2023?

In the year 2023, Kangmei Pharmaceutical Co distributed 0 CNY as dividends.

In which currency does Kangmei Pharmaceutical Co pay out the dividend?

The dividends of Kangmei Pharmaceutical Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kangmei Pharmaceutical Co

Our stock analysis for Kangmei Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kangmei Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.